Eluciderm, Inc. Announces U.S. FDA Clearance of IND Application for ELU42
'The FDA's IND clearance of ELU42 marks an exciting transition for Eluciderm from preclinical research to full clinical-stage company,' said Daniel D. Holsworth, PhD, Chief Executive Officer of Eluciderm.
Share
'The FDA's IND clearance of ELU42 marks an exciting transition for Eluciderm from preclinical research to full clinical-stage company,' said Daniel D. Holsworth, PhD, Chief Executive Officer of Eluciderm. 'ELU42 is the first in our pipeline of Wnt signaling modulators developed around a novel mechanistic approach to tissue healing and repair that we believe will shift the paradigm from simply managing patients' wounds to truly healing them.'
The ELU42 Phase 1/2a trial is an open-label study evaluating the topical spray for safety and efficacy in a cohort of 15 patients with diabetic foot ulcers (DFUs). The study is set to begin the first week of August 2025 at three U.S. sites and will assess multiple clinical endpoints, including wound area reduction, closure rates, and safety metrics. The data from this trial will establish the foundation of a Phase 2 clinical trial in 2026, with strong potential for a Breakthrough Therapy designation in early 2027.
'This first-in-human trial is a defining moment for Eluciderm. ELU42 has the potential to change the standard of care for patients worldwide who suffer from non-healing wounds and underscores our commitment to transforming wound care,' said John P. Delgado, MD, Chief Medical Officer of Eluciderm. 'We believe everyone can be a SuperHealer TM.'
About Eluciderm, Inc.
Eluciderm is a San Diego-based clinical-stage pharmaceutical company pioneering topical small-molecule therapies that awaken the body's innate healing capacity. The company's approach is grounded in a targeted mechanism of action that selectively modulates the Wnt signaling pathway, with the goal of redefining wound healing and clinical outcomes. Eluciderm's platform, anchored by ELU42, includes therapeutics designed to promote healing and regenerative repair of a wide variety of wound injuries, including those from third-degree burns, surgical incisions, elastic cartilage reconstructions, pulmonary fibrotic damage from environmental factors, and inflammatory skin diseases. Based on favorable data from the National Cancer Institute's NCI-60 screening program, Eluciderm is also in the early stages of investigating oncological applications of their mechanistic methodology. For more information, visit www.eluciderm.com and follow Eluciderm on LinkedIn.
Forward-Looking Statements
This press release may contain 'forward-looking statements' within the meaning of the United States Private Securities Litigation Reform Act of 1995, including, but not limited to, statements related to the initiation, timing, and progress of clinical trials; the potential therapeutic benefits of ELU42; and the development plans for Eluciderm, Inc.'s pipeline. These forward-looking statements are based on current expectations and beliefs and are subject to a number of risks and uncertainties, including those related to clinical development, regulatory approvals, manufacturing, and commercialization. Actual results may differ materially from those expressed or implied in the forward-looking statements. Eluciderm, Inc. disclaims any obligation to update these statements except as required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
an hour ago
- CNBC
Court scraps some of Rome's demands in UniCredit's BPM bid, keeps Russia exit
An Italian court has scrapped some of the conditions Rome had set to clear UniCredit's takeover offer for Banco BPM, except a request that it stop operating in Russia - which the Milan-based lender may struggle to comply with. The court's ruling published on Saturday fails to dispel uncertainty around the bid, which UniCredit first announced in November and formally launched in April, opening up a battlefront with Italy's conservative government. A representative for UniCredit said the government would now need to issue a new law decree. "UniCredit continues to evaluate the evolving situation and will take all relevant next steps in a timely manner," the spokesperson added. CEO Andrea Orcel was quoted as saying on Friday that a partial annulment of the government's decision could still leave the bank unable to pursue the offer. UniCredit's BPM bid is one of a dozen takeover offers reshaping Italian finance. Like BBVA's bid for Sabadell, which has met resistance in Madrid, it has seen the government emerge as a key player in banking consolidation. UniCredit also faces strong opposition from Germany's government over its investment in Commerzbank. Italy has invoked national security reasons for its decision, a stance that has drawn scrutiny from European Union authorities. "There can be no doubt about the properness" of the order to leave Russia, which is "totally legitimate," the court said in its ruling. Following supervisory demands, UniCredit has sharply cut its exposure to Russia, but it still runs a local subsidiary and needs approval from Russian authorities to leave the country. A Treasury official said Rome was satisfied with the ruling, since the court recognised as lawful the order to quit Russia, deemed the most important of the conditions. UniCredit has been told to cease its activities in Russia by early 2026, apart from payments handled for Western companies. The court axed a government's request that UniCredit keeps Banco BPM's loan-to-deposit ratio unchanged for five years, and that it maintains both its own and Banco BPM's project finance portfolios in Italy. It made non-mandatory a requirement for UniCredit to keep investments in Italian securities at BPM-owned fund manager Anima Holding. Italy set its terms in April using the government's so-called "golden power", which lets it intervene in transactions involving companies deemed strategic. UniCredit in November bid for Banco BPM after the latter became a shareholder in Monte dei Paschi di Siena, fuelling speculation that the government was advancing long-held plans to promote a combination of the two banks. Banco BPM has rejected UniCredit's approach as hostile and on Saturday it asked its suitor to clarify its intentions.
Yahoo
3 hours ago
- Yahoo
Aegis Capital Reaffirms Buy on Atai Life Sciences N.V. (ATAI) with $8 Target
Atai Life Sciences N.V. (NASDAQ:ATAI) is among the . Aegis Capital analysts have reaffirmed their Buy rating on Atai Life Sciences N.V. (NASDAQ:ATAI), with an unchanged price target of $8.00, following the favorable Phase 2b results of the BPL-003 treatment for the company's Treatment Resistant Depression (TRD). Around 193 depression patients, who didn't respond to previous treatment, were part of the Phase 2b trial testing three doses: 0.3 mg, 8 mg, and 12 mg. Not only the 8mg but also the 12mg dose showcased statistically significant improvement in an FDA-accepted measurement of depression, with a healthy side-effect profile. A close-up of a medical professional providing advice to a patient struggling with opioid use disorder. The research firm believes these robust results strengthen the company's efforts to proceed to a Phase 3 clinical program, which would result in marketing approval. Going forward, Atai Life Sciences N.V. (NASDAQ:ATAI) plans to schedule a post-Phase 2 meeting with the FDA, with the Phase 3 trial expected to begin only at the end of the upcoming year. Another noteworthy development is the company's recent $50 million private capital raise, which involved the sale of 18,264,840 common shares with 25% warrant coverage at the market price. Moves like these highlight Atai Life Sciences N.V. (NASDAQ:ATAI)'s capacity to raise cash when needed. Atai Life Sciences N.V. (NASDAQ:ATAI) is a German clinical-stage biopharmaceutical company that researches, develops, and markets mental health treatments in the United States, Germany, and Canada. With a market capitalization of $587.639 million, the company is committed to healing mental health disorders. While we acknowledge the potential of ATAI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Business Wire
7 hours ago
- Business Wire
WK KELLOGG INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of WK Kellogg Co
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of WK Kellogg Co (NYSE: KLG) to The Ferrero Group. Under the terms of the proposed transaction, shareholders of WK will receive $23.00 in cash for each share of WK that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
